Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
Jun 04, 2021 |
PLASMA & BIOTHERAPIES
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
Kedrion-Kamada, Anti-COVID IG development update
Apr 21, 2021 |
PLASMA & BIOTHERAPIES
Watch the interview given to LeFontiTV by the CEO of our partner Kamada
Rh&Life, first subject included in the study
Apr 07, 2021 |
PLASMA & BIOTHERAPIES
Two hundred pregnant women to be enrolled over five countries
KIDCARES10, first patient enrolled in pediatric PI study
Apr 02, 2021 |
PLASMA & BIOTHERAPIES
Thirty patients aged 2 to 17 years old to be enrolled over five European countries
Updates on anti-COVID treatment developed by Kamada and Kedrion
Apr 01, 2021 |
PLASMA & BIOTHERAPIES
Top-line results announced from the phase 1/2 clinical trial in Israel
CARES10 clinical trial: last patient treated in the USA
Jan 25, 2021 |
PLASMA & BIOTHERAPIES
Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients
First and Only US Pediatric human rabies Immune globulin Trial
Aug 20, 2020 |
PLASMA & BIOTHERAPIES
Kedrion-Kamada Announce Study Met Its Primary Objective
